SHORT MINI FUTURE - NOVO-NORDISK B | Market Closed - Swiss Exchange 11:20:00 2024-07-04 EDT | ||
| 0.99 CHF | -5.71% |
|
| Current month | +28.57% | ||
| 1 month | -18.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 0.99 | -5.71% |
| 24-07-03 | 1.05 | +29.63% |
| 24-07-02 | 0.81 | +8.00% |
| 24-07-01 | 0.75 | -2.60% |
| 24-06-27 | 0.77 | +4.05% |
Delayed Quote Swiss Exchange
Last update July 04, 2024 at 11:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| MNOASV | |
| ISIN | CH1337890078 |
| Date issued | 2024-05-15 |
| Strike | 1,119 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 1.41 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.35 CHF |
|---|---|
| Lowest since issue | 0.63 CHF |
| Spread | 0.04 CHF |
| Spread % | 4.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Certificates
- MNOASV Certificat
